P&G withdraws Intrinsa NDA
Procter & Gamble withdraws NDA for female testosterone patch Intrinsa, but plans to resubmit the application for the hypoactive sexual desire disorder treatment with additional data from trials in naturally menopausal women. The trials are "nearly complete," the company said. At its Dec. 2 meeting, the Reproductive Health Drugs Advisory Committee agreed that additional safety data is needed because of the potential for broad off-label use (1"The Pink Sheet" Dec. 6, 2004, p. 18). The company was seeking an indication for use in surgically menopausal women...
You may also be interested in...
Further safety studies of Procter & Gamble's testosterone patch Intrinsa are necessary prior to approval because of the potential for broad off-label use of the female sexual dysfunction therapy, FDA's Reproductive Health Drugs Advisory Committee said Dec. 2
The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.
Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.